Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
Want to see AU:CU6 full AI Analyst Report?
CU6 Stock Chart & Stats
AU$3.13
-AU$0.24(-5.69%)
At close: 4:00 PM EST
AU$3.13
-AU$0.24(-5.69%)
Day’s Range― - ―
52-Week RangeAU$1.86 - AU$5.87
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.27M
Market Cap
AU$880.21M
Enterprise ValueAU$702.45M
Total Cash (Recent Filing)AU$226.25M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 26, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding372,971,220
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.46Price Target Upside138.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)AU$3.25M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero‑debt balance sheet reduces interest expense and financial distress risk, providing durable flexibility for a capital‑intensive biotech. This structural strength extends runway relative to leveraged peers, supporting R&D continuity and strategic options without immediate covenant pressure.
Focused Theranostics PlatformA clear platform focus on copper‑based theranostics (Cu‑64/Cu‑67) creates a durable competitive niche in oncology radiopharmaceuticals. Platform science can be applied across tumor types, enabling scalable development paths and potential first‑mover or partnership advantages if clinical/regulatory milestones are met.
Long-run Revenue Growth HistorySustained multi‑year revenue growth through 2024 demonstrates prior commercial or clinical traction and execution capability. That historical growth provides a firmer operational foundation than many pre‑revenue biotechs and supports continued program advancement and partner interest over the medium term.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow, worsening in 2025, creates structural funding pressure. With lengthy development cycles the company must rely on external financing repeatedly, raising dilution risk and potentially constraining program timelines and strategic choices over the coming months.
Widening Operating LossesDeep and increasing losses mean operating expenses materially outstrip revenue, indicating the business is not yet monetizing its pipeline. Persisting unprofitability undermines internal funding capacity, weakens bargaining power with partners, and increases execution risk absent sustained external support.
Shrinking Equity BaseA material decline in shareholders' equity reflects accumulated losses and/or past dilution, reducing the balance sheet buffer to absorb future setbacks. Over time this raises the likelihood of additional, potentially dilutive capital raises and increases cost of capital, limiting strategic flexibility.
Clarity Pharmaceuticals Ltd. News
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$1.86 and its highest was AU$5.87 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Clarity Pharmaceuticals Ltd.’s market cap is AU$880.21M.
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 84 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.153 earnings per share for the quarter, missing the consensus estimate of -AU$0.083 by -AU$0.07.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.15.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 372,971,220 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.153 in its last earnings report, missing expectations of -AU$0.083. Following the earnings report the stock price went up 0.278%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarity Pharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$7.46 (138.18% Upside)
AU$7.46 (138.18% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 89%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$1.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-59.59%
Trailing 12-Months
Asset Growth
86.54%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
CU6 Stock 12 Month Forecast
Average Price Target
AU$7.46
▲(138.18% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Telix Pharmaceuticals
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---